GBC AG keeps MustGrow Biologics at Buy, sets price target at EUR 1.54

Bitget2026/09/30 13:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

GBC AG reiterated a Buy rating on MustGrow Biologics, setting a EUR 1.54 target price for Dec. 31, 2027.
Report flagged a Bayer program milestone, driving C$ 1.36 million in high-margin license revenue in H1 2026.
TerraSante sales stayed supply-constrained; revenue reached about C$ 900,000 by mid-August, up 46% versus full-year 2025.
GBC cut FY 2026 revenue forecast to C$ 3.5 million from C$ 4.5 million; EBITDA seen at C$ -4.58 million.
DCF-based target lowered to C$ 2.51 from C$ 2.7, reflecting the FY 2026 reset, higher risk-free rates.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MustGrow Biologics Corp. published the original content used to generate this news brief via EQS News (Ref. ID: rc_26942) on September 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

GBC AG keeps MustGrow Biologics at Buy, sets price target at EUR 1.54

You may also like

Crypto prices